XFOR analyst estimates

X4 Pharmaceuticals (XFOR) analyst ratings, the average price target and its range, and every firm's latest call.

XFOR analyst ratings and price targets

DateFirmCallTarget
Jul 10, 2026Wells FargoX4 Pharmaceuticals initiated with an Overweight at Wells Fargo$11.00
Jun 2, 2026Leerink PartnersX4 Pharmaceuticals initiated with an Outperform at Leerink$12.00
Mar 9, 2026GuggenheimX4 Pharmaceuticals initiated with a Buy at Guggenheim$12.00
Dec 5, 2025Stifel NicolausX4 Pharmaceuticals price target raised to $10 from $7.50 at Stifel$10.00
Nov 5, 2025Stifel NicolausX4 Pharmaceuticals (XFOR) PT Lowered to $7.50 at Stifel$7.50
Aug 29, 2025Stifel NicolausX4 Pharmaceuticals price target lowered to $9 from $30 at Stifel$9.00
Aug 13, 2025H.C. WainwrightX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright$3.50
Dec 22, 2022Cantor FitzgeraldCantor Fitzgerald Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $3$3.00
Dec 11, 2022Piper SandlerX4 Pharmaceuticals initiated with an Overweight at Piper Sandler$3.00
Nov 30, 2022H.C. WainwrightHC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5$5.00